Nonalcoholic Steatohepatitis
Information
- Disease name
- Nonalcoholic Steatohepatitis
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06342947 | Active, not recruiting | Phase 2 | ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) | April 1, 2024 | December 23, 2024 |
| NCT05084404 | Active, not recruiting | Phase 2 | Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease | October 29, 2021 | June 30, 2023 |
| NCT05809934 | Active, not recruiting | Phase 2 | A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis | March 15, 2023 | October 7, 2025 |
| NCT04971785 | Active, not recruiting | Phase 2 | Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | August 9, 2021 | December 2024 |
| NCT04595474 | Active, not recruiting | Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes | January 14, 2021 | December 30, 2024 | |
| NCT00586313 | Completed | N/A | Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.) | January 2007 | July 2008 |
| NCT00586885 | Completed | N/A | Effects of Alanine in Patients With Nonalcoholic Steatohepatitis | February 2004 | June 2006 |
| NCT00586911 | Completed | Phase 2 | Betaine in Patients With Nonalcoholic Steatohepatitis | January 2003 | June 2006 |
| NCT00590161 | Completed | Phase 2 | Pentoxifylline in Patients With Nonalcoholic Steatohepatitis | December 2006 | December 2010 |
| NCT00740610 | Completed | Phase 2 | Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH) | August 2008 | September 2009 |
| NCT00794716 | Completed | Phase 2 | Pharmacokinetics of NRL972 in Patients With Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) | June 2008 | November 2011 |
| NCT00820651 | Completed | Phase 3 | Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis | November 2009 | April 2012 |
| NCT00856869 | Completed | Phase 1/Phase 2 | Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers | August 2004 | April 2005 |
| NCT00994682 | Completed | Phase 4 | University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) | December 2008 | December 2014 |
| NCT01002547 | Completed | Phase 4 | Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment | June 24, 2010 | December 31, 2016 |
| NCT01016418 | Completed | Phase 1/Phase 2 | Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease | January 2010 | August 2010 |
| NCT01051219 | Completed | Phase 3 | Anti-Fibrotic Effects of Losartan In Nash Evaluation Study | May 2011 | December 2014 |
| NCT01066364 | Completed | Phase 2 | Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis | February 2010 | February 2012 |
| NCT01094158 | Completed | Phase 2 | Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis | November 2010 | January 2012 |
| NCT01205087 | Completed | Phase 2 | Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome | September 2010 | April 2011 |
| NCT01237119 | Completed | Phase 2 | Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis | August 2010 | July 2014 |
| NCT00013598 | Completed | Phase 2 | Treatment of Nonalcoholic Steatohepatitis With Pioglitazone | March 2001 | March 2004 |
| NCT00227110 | Completed | Phase 4 | Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) | October 2002 | January 2006 |
| NCT00267670 | Completed | Phase 2/Phase 3 | Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH | March 2005 | September 2009 |
| NCT00509418 | Completed | Phase 3 | Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis | February 2007 | September 2007 |
| NCT00583999 | Completed | The Role of Leptin Receptors in NASH | January 2006 | June 2009 | |
| NCT01399645 | Completed | Phase 2 | Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes | May 2011 | June 2014 |
| NCT01679197 | Completed | Phase 2 | Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy | October 8, 2012 | July 13, 2016 |
| NCT01828528 | Completed | Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease | April 2013 | August 2016 | |
| NCT01919294 | Completed | Phase 2 | Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS) | July 2013 | January 30, 2017 |
| NCT02077374 | Completed | Phase 2 | A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases | March 2014 | March 2015 |
| NCT02083367 | Completed | Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome | January 2013 | February 2015 | |
| NCT02148471 | Completed | Fatty Acids, Genes and Microbiota in Fatty Liver | October 2003 | August 2015 | |
| NCT02210715 | Completed | Phase 4 | Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients | March 2015 | January 30, 2023 |
| NCT02217475 | Completed | Phase 2 | Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis | September 18, 2014 | June 22, 2017 |
| NCT02412540 | Completed | N/A | Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASH | April 23, 2015 | March 2, 2021 |
| NCT02421094 | Completed | Phase 2 | Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis | September 2015 | September 27, 2016 |
| NCT02442687 | Completed | Phase 2 | JKB-121 for the Treatment of Nonalcoholic Steatohepatitis | August 1, 2015 | September 24, 2017 |
| NCT02510599 | Completed | Phase 2 | Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis | December 2015 | February 28, 2017 |
| NCT02633956 | Completed | Phase 2 | Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) | December 4, 2015 | March 12, 2018 |
| NCT02654977 | Completed | Phase 2 | CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy | September 29, 2015 | November 14, 2019 |
| NCT03061721 | Completed | Phase 2 | Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis | April 6, 2017 | December 15, 2020 |
| NCT03068078 | Completed | N/A | A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes | November 2016 | June 4, 2021 |
| NCT03151798 | Completed | N/A | The Liver Health Study for Patients With NAFLD | August 9, 2017 | April 29, 2023 |
| NCT03248882 | Completed | Phase 2 | Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) | August 22, 2017 | March 27, 2019 |
| NCT03332940 | Completed | Phase 1 | An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH | December 6, 2017 | March 10, 2019 |
| NCT03375008 | Completed | N/A | Predictable MR Index for Nonalcoholic Steatohepatitis (NASH) | September 8, 2016 | August 7, 2018 |
| NCT03439254 | Completed | Phase 3 | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis | August 30, 2017 | September 8, 2022 |
| NCT03445208 | Completed | Phase 1 | A Study of Experimental Medication BMS-986036 Given to Healthy Participants | February 14, 2018 | May 2, 2018 |
| NCT03449446 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | March 21, 2018 | November 19, 2019 |
| NCT03486899 | Completed | Phase 2 | A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis | June 19, 2018 | August 17, 2021 |
| NCT03486912 | Completed | Phase 2 | A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis | June 12, 2018 | September 14, 2021 |
| NCT03656744 | Completed | Phase 2 | A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) | November 26, 2018 | March 9, 2020 |
| NCT03674476 | Completed | Phase 1 | An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function | September 11, 2018 | June 24, 2019 |
| NCT03683589 | Completed | De Novo Lipogenesis in Severity of NAFLD | February 1, 2019 | July 31, 2020 | |
| NCT03723252 | Completed | Phase 3 | Dapagliflozin Efficacy and Action in NASH | March 20, 2019 | March 28, 2024 |
| NCT03861819 | Completed | N/A | Feasibility of VIIT in Adults With NASH | January 1, 2018 | December 7, 2018 |
| NCT03987074 | Completed | Phase 2 | Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) | July 29, 2019 | July 13, 2020 |
| NCT04031729 | Completed | Phase 1/Phase 2 | Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease | September 12, 2019 | February 23, 2023 |
| NCT04137055 | Completed | Phase 1 | Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics | November 19, 2019 | December 9, 2020 |
| NCT04152473 | Completed | Phase 1 | Safety and Tolerability of Oral Proglumide for NASH | December 13, 2019 | September 9, 2022 |
| NCT04166773 | Completed | Phase 2 | A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) | November 19, 2019 | January 10, 2024 |
| NCT04210245 | Completed | Phase 2 | Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) | March 23, 2020 | February 23, 2023 |
| NCT04235205 | Completed | Phase 2 | Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease | January 29, 2020 | September 30, 2021 |
| NCT04342793 | Completed | Phase 2 | A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH | December 4, 2019 | May 11, 2021 |
| NCT04389775 | Completed | Phase 1 | To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants | March 29, 2020 | September 29, 2021 |
| NCT04399538 | Completed | Phase 2 | Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis | August 10, 2020 | April 28, 2022 |
| NCT04462081 | Completed | Non Alcoholic Fatty Liver Disease and Coronary Heart Disease in Type 2 Diabetes Patients | January 2013 | January 2015 | |
| NCT04828551 | Completed | N/A | Noninvasive Biomarkers of Metabolic Liver Disease 1.1 | March 18, 2021 | November 20, 2021 |
| NCT04887038 | Completed | Phase 1 | First-in-Human Study of SRT-015 in Healthy Subjects. | May 3, 2021 | February 28, 2022 |
| NCT04944992 | Completed | Phase 2 | A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | August 4, 2021 | October 19, 2022 |
| NCT05309642 | Completed | N/A | Nonalcoholic Fatty Liver Disease - Intermittent Calorie Restriction (FLICR) Study | March 7, 2022 | December 6, 2023 |
| NCT05343780 | Completed | Phase 2 | Clinical Trial to Investigate the Anti-oxidant Activity of Heptex in Patients With Apparent Risk Factors of NASH | May 8, 2019 | February 21, 2022 |
| NCT05560607 | Completed | Phase 1 | Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease | August 12, 2022 | February 27, 2024 |
| NCT05792423 | Completed | N/A | Conditionally Increased Output (CIO) Enhanced Ultrasound System | June 30, 2023 | May 31, 2024 |
| NCT05824156 | Completed | Phase 2 | CM-101 in NASH Patients - The SPLASH Study | February 24, 2021 | August 25, 2022 |
| NCT05983328 | Completed | Phase 1 | Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers | May 10, 2016 | February 9, 2018 |
| NCT03282305 | Not yet recruiting | Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD/NASH in Chinese | April 2018 | December 2029 | |
| NCT05731596 | Not yet recruiting | Phase 3 | Comparative Clinical Study to Evaluate the Efficacy and Safety of Rosuvastatin Vs CoQ10 on Nonalcoholic Steatohepatitis | June 2023 | April 2024 |
| NCT03970031 | Not yet recruiting | Phase 3 | A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH | June 2022 | September 2024 |
| NCT02933554 | Not yet recruiting | N/A | Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis | June 2024 | June 2027 |
| NCT06465186 | Not yet recruiting | Phase 2 | A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) | July 18, 2024 | May 15, 2026 |
| NCT05526144 | Recruiting | Phase 2 | Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans | April 1, 2023 | March 31, 2029 |
| NCT05211284 | Recruiting | Phase 2 | Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US | September 26, 2022 | March 1, 2025 |
| NCT05877547 | Recruiting | Phase 2 | A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) | June 23, 2023 | December 5, 2025 |
| NCT05330923 | Recruiting | Effect of NNRTI or INSTI on Nonalcoholic Steatosis in HIV/AIDS Patients | May 1, 2022 | January 1, 2027 | |
| NCT05979779 | Recruiting | Phase 2 | Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis | September 5, 2023 | April 2025 |
| NCT05430178 | Recruiting | N/A | Metabolic Pathology of Pediatric NAFLD | May 25, 2022 | June 2026 |
| NCT05655221 | Recruiting | Phase 1 | A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects | August 30, 2022 | January 30, 2024 |
| NCT05680233 | Recruiting | Phase 1 | Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis | January 23, 2023 | April 2024 |
| NCT04389593 | Recruiting | Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology as Reference | May 21, 2019 | August 31, 2024 | |
| NCT05720663 | Recruiting | Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis | April 19, 2023 | December 2027 | |
| NCT05733897 | Recruiting | Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis | June 10, 2022 | July 1, 2025 | |
| NCT04501406 | Recruiting | Phase 2 | Low-Dose Pioglitazone in Patients With NASH (AIM 2) | December 15, 2020 | August 31, 2027 |
| NCT04550481 | Recruiting | Phase 2 | Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study | May 11, 2021 | October 30, 2024 |
| NCT02815891 | Recruiting | A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) | July 2016 | July 2036 | |
| NCT04801849 | Recruiting | Phase 2 | Vitamin E Dosing Study | August 5, 2022 | August 30, 2025 |
| NCT06365580 | Recruiting | Phase 1 | Dose Escalation Study of Kylo-0603 in Healthy Subjects | May 23, 2023 | June 30, 2024 |
| NCT05011305 | Recruiting | Phase 2 | Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis | August 18, 2021 | July 2025 |
| NCT05029583 | Recruiting | N/A | Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D) | August 11, 2021 | October 5, 2025 |
| NCT05083390 | Recruiting | Phase 2 | Norursodeoxycholic Acid vs. Placebo in NASH | July 8, 2019 | April 2025 |
| NCT05165706 | Recruiting | N/A | Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | January 31, 2019 | December 30, 2024 |
| NCT01355575 | Terminated | Phase 4 | Rifaximin in Fatty Liver Disease | May 2011 | September 2012 |
| NCT03329885 | Terminated | Phase 1/Phase 2 | A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis | November 2, 2017 | June 26, 2018 |
| NCT03028740 | Terminated | Phase 3 | AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) | April 5, 2017 | March 9, 2021 |
| NCT03676231 | Terminated | Phase 2 | Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH) | January 18, 2019 | May 1, 2019 |
| NCT03053050 | Terminated | Phase 3 | Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis | February 13, 2017 | June 19, 2019 |
| NCT03053063 | Terminated | Phase 3 | Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | January 30, 2017 | May 6, 2019 |
| NCT03059446 | Terminated | Phase 2 | Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis | February 14, 2017 | January 5, 2021 |
| NCT04565717 | Terminated | Phase 1 | A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) | October 9, 2020 | December 21, 2023 |
| NCT04583423 | Terminated | Phase 2 | A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) | November 11, 2020 | April 13, 2023 |
| NCT01260246 | Terminated | N/A | Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes | December 2010 | April 2015 |
| NCT00878592 | Terminated | N/A | Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity | October 2008 | |
| NCT04147195 | Terminated | Phase 2 | Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH) | June 4, 2020 | January 6, 2022 |
| NCT02792634 | Unknown status | Pathogenesis of Non-alcoholic Steatohepatitis and Liver Regeneration After Bariatric Surgery | June 2016 | December 2022 | |
| NCT04012242 | Unknown status | Innovative Liver Elasticity, Attenuation, and Dispersion Ultrasound Study | June 15, 2019 | July 31, 2022 | |
| NCT04710524 | Unknown status | Phase 2 | FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis | June 10, 2021 | August 31, 2023 |
| NCT03725631 | Unknown status | N/A | Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD | September 1, 2016 | August 31, 2019 |
| NCT00152711 | Unknown status | N/A | Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis | September 2004 | |
| NCT00699036 | Unknown status | Phase 2 | Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH) | April 2007 | August 2009 |
| NCT02307344 | Unknown status | N/A | Effect of Nigella Sativa on Nonalcoholic Steatohepatitis and Steatosis | January 2015 | January 2017 |
| NCT05012423 | Unknown status | Phase 1 | FTIH Study of ECC0509 in Healthy Volunteers | July 7, 2021 | February 20, 2022 |
| NCT03602573 | Unknown status | Liver Fibrosis in Peri-menopausal Women | August 1, 2018 | July 31, 2019 | |
| NCT02717000 | Unknown status | NASH: Non-invasive Diagnostic Markers and Imaging | April 2016 | December 2017 | |
| NCT02764047 | Unknown status | N/A | Probiotics in the Treatment of NAFLD | January 2015 | January 2018 |
| NCT00842205 | Unknown status | N/A | Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection | January 2007 | December 2009 |
| NCT02574325 | Unknown status | Phase 2 | A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis | October 2015 | December 2016 |
| NCT04216693 | Withdrawn | Phase 2 | Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH) | June 1, 2020 | June 1, 2023 |
| NCT03163810 | Withdrawn | N/A | A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH) | February 6, 2017 | December 13, 2017 |
| NCT01466894 | Withdrawn | Phase 2 | Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis | December 2012 | December 2013 |
| NCT02769091 | Withdrawn | Phase 2 | A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes | September 30, 2016 | February 28, 2018 |